 CAMBRIDGE, Mass., March 30, 2021 PRNewswire -- Akebia Therapeutics , Inc. Nasdaq: AKBA, a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced that it has submitted a New Drug Application NDA to the U.S. Food and Drug Administration FDA for vadadustat, Akebias investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor HIF-PHI, for the treatment of anemia due to chronic kidney disease CKD in both adult patients on dialysis and adult patients not on dialysis. 